A MUC1 peptide vaccine didn't significantly reduce overall colorectal adenoma recurrence, but the subset of patients who mounted a strong immune response saw a striking 38% absolute reduction in polyp recurrence.
27.3% vs. 66.0% recurrenceAmong patients who mounted a strong immune response to the MUC1 peptide vaccine at both timepoints, only 27.3% developed recurrent adenomas — compared to 66% in the placebo group — a 38% absolute reduction.
What the researchers found
In this double-blind, placebo-controlled trial, the MUC1 peptide vaccine successfully generated immune responses in 25% of recipients (13/52) — significantly more than placebo (0/50, p < 0.0001). However, the overall adenoma recurrence rate was not significantly different between vaccine (56.3%) and placebo (66.0%) groups (adjusted RR 0.83, p = 0.25). The most intriguing finding was among the subset who mounted a robust immune response at both 12 and 55 weeks: only 27.3% (3/11) developed recurrent adenomas versus 66% in the placebo group — a 38% absolute reduction (adjusted RR 0.41, p = 0.08). The vaccine showed no difference in serious adverse events compared to placebo.
Why it matters
This is one of the first randomized controlled trials testing a peptide vaccine to prevent precancerous colon polyps (adenomas) from coming back — a cancer prevention strategy rather than cancer treatment. While the overall result was negative, the dramatic reduction in adenoma recurrence among strong immune responders (27.3% vs. 66%) suggests the vaccine concept works, but only in people whose immune systems respond robustly. This points toward a future where peptide vaccines might prevent cancer in people who can mount adequate immune responses.
The numbers in context
n=103 (53 vaccine, 50 placebo) · 25% immune response rate (13/52) · Overall recurrence: 56.3% vs. 66.0% (p=0.25) · Strong responders: 27.3% vs. 66.0% recurrence (p=0.08) · 38% absolute reduction in responders
How the study worked
This multicenter, double-blind, placebo-controlled RCT enrolled 103 adults aged 40-70 with a recent advanced colorectal adenoma. Participants received either the MUC1 peptide vaccine or placebo at weeks 0, 2, and 10, with a booster at week 53. The primary endpoint was vaccine immunogenicity (≥2-fold increase in anti-MUC1 IgG at 12 weeks). Secondary endpoints included adenoma recurrence assessed at ≥1 year from randomization.
Who was studied
103 adults aged 40-70 with recent advanced colorectal adenoma, randomized to MUC1 peptide vaccine or placebo
What this study cannot tell us
Only 25% of vaccine recipients mounted an immune response, limiting the vaccine's population-level efficacy. The study was small (n=103) and may have been underpowered to detect the overall adenoma reduction as significant. The dramatic result in strong responders (p=0.08) did not reach statistical significance and involved only 11 patients. There is no way to predict in advance who will respond to the vaccine. The study does not explain why 75% of recipients failed to generate an immune response.
How to read the evidence
This is a well-designed, multicenter, double-blind, placebo-controlled RCT — the gold standard for clinical evidence. However, the overall primary clinical outcome (adenoma recurrence) was not statistically significant. The impressive result in immune responders is a subgroup analysis with only 11 patients and p=0.08, which doesn't meet conventional significance thresholds.
When this study was published
Published in 2023 in Clinical Cancer Research, this is a recent and important trial in the emerging field of cancer prevention vaccines. The results are actively informing the design of next-generation peptide vaccines with improved immunogenicity.
The bigger picture
Cancer vaccines have mostly been studied as treatments for existing cancer, with mixed results. Using a peptide vaccine to prevent cancer (or precancer) from developing represents a paradigm shift — closer to how we think about infectious disease vaccines. MUC1 is an attractive target because it's overexpressed and abnormally glycosylated on many cancer types. This trial, while small and technically negative, provides proof-of-concept that immune responses against a cancer-associated peptide can translate into reduced precancer recurrence, potentially opening the door to cancer prevention vaccines.
Questions still open
- Can the vaccine formulation or delivery be modified to increase the immune response rate beyond 25%?
- What biological factors determine whether a person will respond to the MUC1 peptide vaccine, and can non-responders be identified in advance?
- Would a larger trial powered to detect the effect seen in immune responders (38% absolute reduction) confirm the cancer-preventive benefit?
Common questions
Did the vaccine work?
Could this eventually prevent colon cancer?
Read the original research
Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma.
Clinical cancer research : an official journal of the American Association for Cancer Research, 29(9), 1678-1688
Citation
Schoen, Robert E; Boardman, Lisa A; Cruz-Correa, Marcia; Bansal, Ajay; Kastenberg, David; Hur, Chin; Dzubinski, Lynda; Kaufman, Sharon F; Rodriguez, Luz M; Richmond, Ellen; Umar, Asad; Szabo, Eva; Salazar, Andres; McKolanis, John; Beatty, Pamela; Pai, Reetesh K; Singhi, Aatur D; Jacqueline, Camille M; Bao, Riyue; Diergaarde, Brenda; McMurray, Ryan P; Strand, Carrie; Foster, Nathan R; Zahrieh, David M; Limburg, Paul J; Finn, Olivera J. (2023). Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma.. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(9), 1678-1688. https://doi.org/10.1158/1078-0432.CCR-22-3168